Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas. Its products under preclinical stage include SL-301, a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types; SL-101, a mAb-based compound that targets CD123; SL-201, a small molecule active against certain hematologic and solid tumor types; and SL-601, mAb-based compound that targets a cell surface marker on bladder CSCs. The company also in-licensed intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened, and Patched. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
August 11, 2021
RegMed Investors’ (RMi) closing bell: volatility sucks pond water
August 10, 2021
RegMed Investors’ (RMi) closing bell: earnings’ season is not for the faint-of-heart sector investor
August 9, 2021
RegMed Investors’ (RMi) closing bell: as good as gets in these markets as sentiment wains
August 6, 2021
RegMed Investors’ (RMi) closing bell: Back from the morning’s brink, safety is managing risk
August 5, 2021
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector’s hot with a low volume rally
August 4, 2021
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector peaks and dives as sentiment remains unsupported
August 3, 2021
RegMed Investors’ (RMi) closing bell: the sector just can’t keep the upside candle lit
August 2, 2021
RegMed Investors’ (RMi) closing bell: weekly expectation versus upcoming reality
July 30, 2021
RegMed Investors’ (RMi) closing bell: last session in July with an ugly month for the cell and gene therapy sector’s pricings
July 29, 2021
RegMed Investors’ (RMi) closing bell: in the blink of an eye or a mid-day dive, the oversold became the overbought
35 companies, 1 interpreter!
Insight, foresight and recommendation
Stemline Therapeutics (STML) -- STML opened on 1/2/18 at $15.65 and closed on 3/31 at $15.85 and March at $16.75 with a high (3/6/18) at 17.20 ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.